Divij Mathew

Divij Mathew

Auto-generated profile, based on publicly available information

Divij Mathew

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Science
Verified
Journal Article
Open access
PDF file
DMDivij Mathew
Divij Mathew
JGJosephine R. Giles
Josephine R. Giles
ABAmy E. Baxter
Amy E. Baxter
DODerek A. Oldridge
Derek A. Oldridge
AGAllison R. Greenplate
Allison R. Greenplate
AVAshley N. Vanderbeck
Ashley N. Vanderbeck
Immune profiling of COVID-19 patients: Coronavirus disease 2019 (COVID-19) has affected millions of people globally, yet how the human immune system responds to and influences COVID-19 severity remains unclear. Mathew et al. present a comprehensive atlas of immune modulation associated with COVID-19. They performed high-dimensional flow cytometry of hospitalized COVID-19 patients and found three prominent and distinct immunotypes that are related to disease severity and clinical parameters. Arunachalam et al. report a systems biology approach to assess the immune system of COVID-19 patients with mild-to-severe disease. These studies provide a compendium of immune cell information and roadmaps for potential therapeutic interventions. Science , this issue p. eabc8511 , p. 1210

3 December 2021 in Science
Verified
Journal Article
Open access
RGRishi R. Goel
Rishi R. Goel
MPMark M. Painter
Mark M. Painter
SASokratis A. Apostolidis
Sokratis A. Apostolidis
DMDivij Mathew
Divij Mathew
WMWenzhao Meng
Wenzhao Meng
AVA. N. Vanderbeck
A. N. Vanderbeck
Immune memory after vaccination: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven highly effective at preventing severe COVID-19. However, the evolution of viral variants, and waning antibody levels over time, raise questions regarding the longevity of vaccine-induced immune protection. Goel et al . examined B and T lymphocyte responses in individuals who received SARS-CoV-2 messenger RNA vaccines. They performed a 6-month longitudinal study of individuals who never had SARS-CoV-2 infection compared with people who had recovered from SARS-CoV-2. Humoral and cellular immune memory was observed in vaccinated individuals, as were functional immune responses against the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) viral variants. Analysis of T cell activity suggested that robust cellular immune memory may prevent hospitalization by limiting the development of severe disease. —PNK

3 July 2020 in Science Immunology
Verified
Journal Article
Open access
PDF file
LKLeticia Kuri-Cervantes
Leticia Kuri-Cervantes
MPMaria Betina Pampena
Maria Betina Pampena
WMWenzhao Meng
Wenzhao Meng
ARAaron M. Rosenfeld
Aaron M. Rosenfeld
CICaroline A. G. Ittner
Caroline A. G. Ittner
MBMichael R. Betts
Michael R. Betts
Profound plasmablast expansion, innate cell modulation, and T cell activation are defining features of severe COVID-19.

2 April 2021 in Science Immunology
Verified
Journal Article
Open access
PDF file
RGRishi R. Goel
Rishi R. Goel
SASokratis A. Apostolidis
Sokratis A. Apostolidis
MPMark M. Painter
Mark M. Painter
DMDivij Mathew
Divij Mathew
APAjinkya Pattekar
Ajinkya Pattekar
EWE. John Wherry
E. John Wherry
Key differences in both antibody and memory B cell responses to mRNA vaccination were identified on the basis of prior SARS-CoV-2 exposure.

14 September 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SASokratis A. Apostolidis
Sokratis A. Apostolidis
MKMihir Kakara
Mihir Kakara
MPMark M. Painter
Mark M. Painter
RGRishi R. Goel
Rishi R. Goel
DMDivij Mathew
Divij Mathew
ABAmit Bar-Or
Amit Bar-Or
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine-induced responses in immunosuppressed patients. We investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis (MS) on anti-CD20 antibody monotherapy (n = 20) compared with healthy controls (n = 10) after BNT162b2 or mRNA-1273 mRNA vaccination. Treatment with anti-CD20 monoclonal antibody (aCD20) significantly reduced spike-specific and receptor-binding domain (RBD)-specific antibody and memory B cell responses in most patients, an effect ameliorated with longer duration from last aCD20 treatment and extent of B cell reconstitution. By contrast, all patients with MS treated with aCD20 generated antigen-specific CD4 and CD8 T cell responses after vaccination. Treatment with aCD20 skewed responses, compromising circulating follicular helper T (TFH) cell responses and augmenting CD8 T cell induction, while preserving type 1 helper T (TH1) cell priming. Patients with MS treated with aCD20 lacking anti-RBD IgG had the most severe defect in circulating TFH responses and more robust CD8 T cell responses. These data define the nature of the SARS-CoV-2 vaccine-induced immune landscape in aCD20-treated patients and provide insights into coordinated mRNA vaccine-induced immune responses in humans. Our findings have implications for clinical decision-making and public health policy for immunosuppressed patients including those treated with aCD20.

20 May 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EBErin M. Bange
Erin M. Bange
NHNicholas A. Han
Nicholas A. Han
PWPaul Wileyto
Paul Wileyto
JKJustin Y. Kim
Justin Y. Kim
SGSigrid Gouma
Sigrid Gouma
AHAlexander C. Huang
Alexander C. Huang